Eptifibatide
Alternative Names: Integrelin; Integrilin; Intrifiban; SCH 60936Latest Information Update: 03 May 2024
At a glance
- Originator Millennium Pharmaceuticals
- Developer GSK; Merck & Co; Millennium Pharmaceuticals; Schering-Plough
- Class Ischaemic heart disorder therapies; Peptides
- Mechanism of Action Fibrinogen receptor antagonists; GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute coronary syndromes; Myocardial infarction; Unstable angina pectoris
- Discontinued Stroke
Most Recent Events
- 29 Apr 2024 Eptifibatide generic equivalent available in USA for Acute coronary syndromes and Angioplasty
- 30 Mar 2009 Discontinued - Phase-III for Acute coronary syndromes in World (IV)
- 15 Oct 2008 Safety and efficacy data from the three-year ASSIST trial in Myocardial infarction released by the University of Ottawa Heart Institute